This new trial, a single-blind, randomised Phase II trial, will enrol 300 volunteers, with up to 240 of these volunteers receiving the ChAdOx1 nCoV-19 vaccine and the remainder a control meningitis vaccine, which has been shown to be safe in children but is expected to produce similar reactions, such as a sore arm.
Backing the 12-16 weeks gap between the two doses of Covishield in the country, the chief investigator of the AstraZeneca vaccine clinical trials on Friday said that the level of protection provided by one dose of the preventive significantly increases in the second and third months after the jab.
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
Doses of the vaccine were given to 1,077 healthy adults aged between 18 and 55 in five United Kingdom hospitals in April and May as part of the phase one clinical trial.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances